carvedilol has been researched along with Ewing Sarcoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duckett, MM | 1 |
| Phung, SK | 1 |
| Nguyen, L | 1 |
| Khammanivong, A | 1 |
| Dickerson, E | 1 |
| Dusenbery, K | 1 |
| Lawrence, J | 1 |
1 other study available for carvedilol and Ewing Sarcoma
| Article | Year |
|---|---|
The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells.
Topics: Adrenergic beta-Antagonists; Animals; Bone Neoplasms; Carvedilol; Cell Line, Tumor; Dog Diseases; Do | 2020 |